Bridge Securities Ltd vs Genomic Valley Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 16, 2026

Key Highlights

The Latest Trading Price of Bridge Securities Ltd is ₹ 12.15 as of 16 Mar 15:30 . The P/E Ratio of Bridge Securities Ltd changed from 1.1 on March 2021 to 2.5 on March 2025 . This represents a CAGR of 17.84% over 5 yearsThe P/E Ratio of Genomic Valley Biotech Ltd changed from 694.2 on March 2024 to 50.1 on March 2025 . This represents a CAGR of -73.14% over 2 years The Market Cap of Bridge Securities Ltd changed from ₹ 1.39 crore on March 2021 to ₹ 37.55 crore on March 2025 . This represents a CAGR of 93.34% over 5 yearsThe Market Cap of Genomic Valley Biotech Ltd changed from ₹ 10.6 crore on March 2024 to ₹ 17.9 crore on March 2025 . This represents a CAGR of 29.95% over 2 years The revenue of Bridge Securities Ltd for the Dec '25 is ₹ 0.42 crore as compare to the Sep '25 revenue of ₹ 0.42 crore. This represent the decline of 0% The revenue of Genomic Valley Biotech Ltd for the Dec '25 is ₹ 0.05 crore as compare to the Sep '25 revenue of ₹ 0.09 crore. This represent the decline of -44.44% The ebitda of Bridge Securities Ltd for the Dec '25 is ₹ 0.34 crore as compare to the Sep '25 ebitda of ₹ 0.4 crore. This represent the decline of -15% The ebitda of Genomic Valley Biotech Ltd for the Dec '25 is ₹ 0.01 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The net profit of Bridge Securities Ltd changed from ₹ 0.03 crore to ₹ 0.33 crore over 7 quarters. This represents a CAGR of 293.62% The net profit of Genomic Valley Biotech Ltd changed from ₹ 0.13 crore to ₹ 0.01 crore over 7 quarters. This represents a CAGR of -76.91% The Dividend Payout of Bridge Securities Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Genomic Valley Biotech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bridge Securities Ltd

Bridge Securities Limited was incorporated in December, 1994.
Although engaged in various sectors such as Banking, Hospitality Industry or Agro-industry; Teyliom Group has undertaken a partnership with Tunisie Valeurs/ operating on the TUNISIAN financial market, to launch a Management and Intermediation Company (MIC) known as 'Bridge Securities' and was approved by the Regional Council for Public Savings and Capital Markets (CREPMF) in January 2017. The Company is engaged in securities trading, stock broking and leasing.
Its mission applies to the Waemu financial market with Capital Markets offer, intended for a clientele looking to optimize their liquid assets through bond securities acquisition or listed shares.
Its expertise covers the financial engineering fields by finding appropriate solutions to the financing requirements for company's operation and investment.

About Genomic Valley Biotech Ltd

Incorporated in May 1994, Genomic Valley Biotech Limited is formed with the objective of conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market nationally as well as internationally.
The Company is extensively involved in commercial greenhouse / poly house cultivation of crops.
Presently, it is engaged in high-tech cultivation through environmental controlled Poly Houses,NFT & DFT etc,manufacturing of Tissue Cultured Improved variety of plants and organic farming using Bio-Fertilizer.
Also it is involved in commercial Horticulture activities with Aloe vera, Tomato, Bitter Gourd, Bottle Gourd, Brinjal, Broccoli, Cabbage, Capsicum, Carrot, Cauliflower, Cucumber, Green Chillies, Onion, Radish, Ridge/Sponge Gourd, Leafy Vegetables, Pumpkin, Banana, Guava, Papaya, and Strawberry.

FAQs for the comparison of Bridge Securities Ltd and Genomic Valley Biotech Ltd

Which company has a larger market capitalization, Bridge Securities Ltd or Genomic Valley Biotech Ltd?

Market cap of Bridge Securities Ltd is 46 Cr while Market cap of Genomic Valley Biotech Ltd is 7 Cr

What are the key factors driving the stock performance of Bridge Securities Ltd and Genomic Valley Biotech Ltd?

The stock performance of Bridge Securities Ltd and Genomic Valley Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bridge Securities Ltd and Genomic Valley Biotech Ltd?

As of March 16, 2026, the Bridge Securities Ltd stock price is INR ₹12.08. On the other hand, Genomic Valley Biotech Ltd stock price is INR ₹24.99.

How do dividend payouts of Bridge Securities Ltd and Genomic Valley Biotech Ltd compare?

To compare the dividend payouts of Bridge Securities Ltd and Genomic Valley Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.